Atai Life Sciences N.V. (ATAI)
Largest Insider Buys in Sector
ATAI Stock Price History Chart
ATAI Stock Performance
About Atai Life Sciences N.V.
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of …
Insider Activity of Atai Life Sciences N.V.
Over the last 12 months, insiders at Atai Life Sciences N.V. have bought $0 and sold $521,476 worth of Atai Life Sciences N.V. stock.
On average, over the past 5 years, insiders at Atai Life Sciences N.V. have bought $8.29M and sold $521,476 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $23,120 was made by Brand Florian (See Remarks) on 2023‑11‑16.
List of Insider Buy and Sell Transactions, Atai Life Sciences N.V.
| 2024-05-16 | Sale | See Remarks | 151,303 0.09% | $1.92 | $290,502 | -29.57% | ||
| 2024-04-02 | Sale | See Remarks | 61,640 0.0367% | $1.85 | $114,034 | -26.20% | ||
| 2024-04-02 | Sale | Chief Financial Officer | 27,410 0.0163% | $1.85 | $50,709 | -26.20% | ||
| 2024-04-02 | Sale | Chief Business Officer | 35,801 0.0213% | $1.85 | $66,232 | -26.20% | ||
| 2023-11-16 | See Remarks | 20,000 0.0125% | $1.16 | $23,120 | +41.10% | |||
| 2023-09-13 | See Remarks | 40,000 0.0242% | $1.45 | $57,968 | +5.67% | |||
| 2023-03-29 | 10 percent owner | 1.21M 0.6461% | $1.32 | $1.6M | +8.33% | |||
| 2023-03-29 | See Remarks | 70,000 0.0418% | $1.48 | $103,558 | +8.33% | |||
| 2022-04-28 | 21,900 0.0144% | $4.47 | $97,801 | -28.96% | ||||
| 2022-04-26 | 19,803 0.013% | $4.64 | $91,939 | -31.30% | ||||
| 2022-04-22 | 52,820 0.0346% | $4.83 | $254,962 | -33.79% | ||||
| 2022-04-20 | 68,688 0.0434% | $4.95 | $340,040 | -37.52% | ||||
| 2022-04-18 | 54,322 0.0353% | $5.11 | $277,656 | -37.38% | ||||
| 2022-04-14 | 4,967 0.0031% | $5.19 | $25,779 | -39.38% | ||||
| 2022-04-12 | 55,197 0.0356% | $4.88 | $269,560 | -33.94% | ||||
| 2022-04-08 | 57,689 0.0364% | $4.81 | $277,640 | -33.54% | ||||
| 2021-06-22 | 10 percent owner | 700,000 0.4218% | $15.00 | $10.5M | -57.97% | |||
| 2021-06-22 | 700,000 0.4218% | $15.00 | $10.5M | -57.97% | ||||
| 2021-06-22 | director | 4,666 0.0028% | $15.00 | $69,990 | -57.97% | |||
| 2021-06-22 | Chief Financial Officer | 4,666 0.0028% | $15.00 | $69,990 | -57.97% |
Insider Historical Profitability
| Brand Florian | See Remarks | 328697 0.1959% | $1.59 | 4 | 1 | <0.0001% |
| Rao Srinivas | See Remarks | 113360 0.0676% | $1.59 | 1 | 1 | <0.0001% |
| Apeiron Investment Group Ltd. | 10 percent owner | 32086697 19.1218% | $1.59 | 2 | 0 | <0.0001% |
| Auerbach Michael | director | 5564474 3.3161% | $1.59 | 1 | 0 | <0.0001% |
| Angermayer Christian | 1799302 1.0723% | $1.59 | 9 | 0 | <0.0001% |
Institutional Investor Ownership
| Morgan Stanley | $5.26M | 1.59 | 2.67M | -15.21% | -$942,917.27 | <0.0001 | |
| Millennium Management LLC | $4.37M | 1.32 | 2.22M | +191.36% | +$2.87M | <0.01 | |
| BlackRock | $2.76M | 0.84 | 1.4M | +3.03% | +$81,227.04 | <0.0001 | |
| Marshall Wace | $1.56M | 0.47 | 793,839 | +2.31% | +$35,361.50 | <0.01 | |
| Brown University | $1.42M | 0.43 | 718,500 | 0% | +$0 | 0.59 |